Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H29O4.K |
| Molecular Weight | 396.5616 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC([O-])=O
InChI
InChIKey=JTZQCHFUGHIPDF-RYVBEKKQSA-M
InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1
| Molecular Formula | C22H29O4 |
| Molecular Weight | 357.4633 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25389106
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25389106
Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body. Potassium canrenoate is not licensed in the UK, but may sometimes be prescribed off-licence to treat oedema. It is given intravenously. Potassium canrenoate is a mineralocorticoid receptor (MR) antagonist. The blockade with MR antagonist have beneficial effects in patients with heart failure and myocardial infarction, often attributed to blocking aldosterone action in the myocardium.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Heterogeneous nuclear ribonucleoprotein A2/B1 is a tissue-specific aldosterone target gene with prominent induction in the rat distal colon. | 2013-01-15 |
|
| Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. | 2010-10 |
|
| Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. | 2010-07 |
|
| Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. | 2010-07 |
|
| The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. | 2010-07 |
|
| Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. | 2010-07 |
|
| Cell and drug delivery therapeutics for controlled renal parenchyma regeneration. | 2010-06-15 |
|
| Amiloride reduces portal hypertension in rat liver cirrhosis. | 2010-06 |
|
| Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. | 2010-06 |
|
| A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. | 2010-05 |
|
| Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors? | 2010-05 |
|
| Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: an assessment. | 2010-04 |
|
| Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. | 2010-01 |
|
| Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay. | 2010 |
|
| Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows. | 2009-09-01 |
|
| Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. | 2009-04-07 |
|
| Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. | 2009-02 |
|
| Responses to diuretic treatment in gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1. | 2009 |
|
| Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay. | 2008-12 |
|
| Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor. | 2008-06 |
|
| Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate. | 2008-04 |
|
| Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. | 2008-01 |
|
| Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. | 2007-12 |
|
| Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. | 2007-11 |
|
| Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. | 2007-10 |
|
| Primary hyperaldosteronism is associated with derangement in the regulation of the hypothalamus-pituitary-adrenal axis in humans. | 2007-09-13 |
|
| A direct effect of aldosterone on endothelin-1 gene expression in vivo. | 2007-04 |
|
| Cirrhotic cardiomyopathy. | 2007-03-27 |
|
| Modulating the development of renal tubules growing in serum-free culture medium at an artificial interstitium. | 2007-02 |
|
| Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis. | 2006-12-01 |
|
| Why are mineralocorticoid receptor antagonists cardioprotective? | 2006-12 |
|
| Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis. | 2006-11 |
|
| Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. | 2006-03 |
|
| Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. | 2006 |
|
| A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone. | 2006 |
|
| Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. | 2005-11 |
|
| Prevention of renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation. | 2005-10-27 |
|
| Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. | 2005-10 |
|
| Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. | 2005-09 |
|
| Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | 2005-08 |
|
| Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. | 2005-05-03 |
|
| Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism. | 2005-05 |
|
| Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. | 2005-03 |
|
| Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. | 2005-03 |
|
| Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. | 2005-01 |
|
| Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model. | 2004-12 |
|
| DNA fragmentation, DNA repair and apoptosis induced in primary rat hepatocytes by dienogest, dydrogesterone and 1,4,6-androstatriene-17beta-ol-3-one acetate. | 2004-11-14 |
|
| Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs. | 2004-10 |
|
| Ouabain-inhibiting activity of aldosterone antagonists. | 1995-01 |
|
| Prevention and abolition of ouabain-induced ventricular tachycardia by potassium canrenoate in dogs. | 1972-08 |
Patents
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:21:41 GMT 2025
by
admin
on
Mon Mar 31 19:21:41 GMT 2025
|
| Record UNII |
M671F9NLEA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C547
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-VATC |
QC03DA02
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-ATC |
C03DA02
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1981
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL1616951
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DB09015
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
C81161
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
M671F9NLEA
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
2448
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
218-554-9
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
757789
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
D002191
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DTXSID2045602
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
23671691
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
POTASSIUM CANRENOATE
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
477
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
100000091863
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
2181-04-6
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
m3023
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB09983MIG
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |